Skip to content
OpenCapital
Get started

aTyr Pharma ATYR Proceeds From Sale And Maturity Of Available For Sale Securities

Proceeds From Sale And Maturity Of Available For Sale Securities at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$359M+63.2%
Design Therapeutics, Inc. logo
Design Therapeutics, Inc.DSGN
——
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
——
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
——
Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE
——
BridgeBio Pharma logo
BridgeBio PharmaBBIO
——

Other financials

Income statement

See full
Revenue-—
Operating income-$11.4M+27.5%
Net income-$10.8M+27.5%
EPS (diluted)-$0.11+35.3%

Balance sheet

See full
Cash & equivalents$10.0M-3.4%
Total debt$12.3M-9.2%
Total equity$57.9M-22.8%
Total assets$79.7M-18.1%

Cash flow

See full
Operating cash flow-$12.5M+18.8%
CapEx$138.0K—
Free cash flow-$12.7M+17.9%

Valuation

See full
Market cap$54.88M-88.2%
Enterprise value$57.17M—
P/S288.8×—

Profitability

See full
Operating margin-40,856.3%+28,833pp
Net margin-39,009.5%+29,653pp
FCF margin-32,664.7%+4,018pp

Returns & leverage

See full
Return on equity-105.3%+50.6pp
Debt / equity0.2×0.0×
Current ratio5.8×-2.0×

Where this comes from

Reported directly by aTyr Pharma in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.

The official record: aTyr Pharma’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about aTyr Pharma's proceeds from sale and maturity of available for sale securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is aTyr Pharma's proceeds from sale and maturity of available for sale securities?
aTyr Pharma (ATYR) reported proceeds from sale and maturity of available for sale securities of $17.5M in Q1 2026.
How has aTyr Pharma's proceeds from sale and maturity of available for sale securities changed year-over-year?
aTyr Pharma's proceeds from sale and maturity of available for sale securities decreased by 6.3% year-over-year, from $18.69M to $17.5M.
What is the long-term trend for aTyr Pharma's proceeds from sale and maturity of available for sale securities?
Over 4 years (2021 to 2025), aTyr Pharma's proceeds from sale and maturity of available for sale securities has grown at a 26.0% compound annual growth rate (CAGR), from $35.08M to $88.46M.